Rapamycin, a potent immunosuppressive drug, causes programmed cell death in В lymphoma cells

Transplantation

Volumn 60, Issue 3, 1995, Pages 264-270

  Muthukkumar, Subramanian ^a   Ramesh, Tennore M ^a   Bondada, Subbarao ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DNA FRAGMENT; DRUG BINDING PROTEIN; IMMUNOGLOBULIN M ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMIDINE; TRITIUM; TSUKUBAENOLIDE BINDING PROTEIN; UNCLASSIFIED DRUG; URIDINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOMA;

ANIMAL; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, ANTI-IDIOTYPIC; APOPTOSIS; B-LYMPHOCYTES; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; MICE; MICE, INBRED CBA; POLYENES; SIROLIMUS; SUPPORT, U.S. GOV'T, P.H.S.; TACROLIMUS; THYMOMA; THYMUS NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0029086748     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199508000-00010     Document Type: Article

References (60)

1. Sehgal SN, Baker H, Vezina C. Rapamycin (AY 22, 989), a new anti-fungal antibiotic II. Fermentation, isolation and characterization. J Antibiot 1975; 28: 727.
2. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55: 48.
3. Morris RE. Rapamycins: antifungal, anti-tumor, anti-prolifera tive and immunosuppressive molecules. Transplant Rev 1992; 6: 39.
4. Sigal NH, Dumont FJ. Cyclosporin A, FK 506 and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519.
5. Caine RY, Collier D, Lim S, et al. Rapamycin for immunosup pression in organ allografting. Lancet 1989; 2: 227.
6. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound [Letter], Med Sci Res 1989; 17: 609.
7. Stepkowski SM, Chen H, Daloze P, Kahn BD. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowl transplantation in the rat. Transplantation 1991; 51: 22.
8. Stepkowski SM, Chen H, Wang M, Daloze P, Kahn BD. Inhibi tion of host-versus-graft and graft-versus host responses after small bowel transplantation in rats by rapamycin. Transplantation 1992; 53: 28.
9. Chen H, Wu J, Xu D, Luo H, Daloze P. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993; 56: 661.
10. Chen H, Wu JP, Luo H, Daloze P. The immunosuppressive effect of rapamycin on pancreaticoduodenal transplants in the rat. Transplant Proc 1991; 23: 2239.
11. Chen H, Wu J, Luo H, Daloze P. Synergistic effect of rapamycin and cyclosporine in pancreaticoduodenal transplantation in the rat. Transplant Proc 1992; 24: 892.
12. Chen H, Wu J, Xu D, et al. The effect of rapamycin on orthotopic small bowel transplantation in the rat. Transplant Proc 1992; 24: 1157.
13. Ochiai T, Sakamoto K, Nagata M, et al. Studies on FK506 in experimental organ transplantation. Transplant Proc 1988; 20: 209.
14. Collier DStJ, Calney RY, Thiru S, et al. FK506 in experimental renal allografts in dogs and primates. Transplant Proc 1988; 20: 226.
15. Turka LA, Goguen JE, Gagne JE, Milford EL. Presensitization and the renal allograft recipient. Transplantation 1989; 47: 234.
16. Thiru S, Caine RY, Nagington J. Lymphoma in renal allograft patients treated with cyclosporin A as one of the immunosuppressive agents. Transplant Proc 1981; 13: 359.
17. Cleary ML, Wamke R, Sklar J. Monoclonality of lymphoprolif-erative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangement. N Engl J Med 1984; 310: 477.
18. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43: 32.
19. Shinozuka H, Gill TJ III, Kunz HW, Witkowski LA, Demetris AJ, Perera MIR. Cyclosporine enhances the induction of murine thymic lymphomas. Transplantation 1986; 41: 377.
20. Hattori A, Perera MIR, Witkowski LA, Kunz HW, Gill TJ III, Shinozuka H. Accelerated development of spontaneous thymic lymphomas in male AKR mice receiving cyclosporine. Transplantation 1986; 41: 784.
21. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 973.
22. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin like growth factor receptor. Cancer Res 1994; 54: 903.
23. Eng CP, Sehgal SN, Vizina C. Activity of rapamycin (AY-22, 989) against transplanted tumors. J Antibiot 1984; 37: 1231.
24. Harding M, Galat A, Uehling D, Schrieber SL. A receptor for immunosuppressant FK506 is a cis-trans peptidyl prolyl isomerase. Nature 1989; 341: 758.
25. Siekerka J, Hung S, Poe M, Lin C, Sigal N. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755.
26. Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transduction pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231.
27. Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schrieber SL. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 1990; 250: 556.
28. Dumont FJ, Staruch MJ, Koprak SC, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK506 and rapamycin. J Immunol 1990; 144: 251.
29. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppres sant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718.
30. Lin CS, Boltz RC, Siekierka JJ, Sigal NH. FK506 and CSA inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol 1991; 133: 269.
31. Schrieber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283.
32. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schrieber SL. Calcinuerin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
33. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear translocation of a T cell transcription factor blocked by FK506 and cyclosporin A. Nature 1991; 352: 803.
34. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227.
35. Kuo CJ, Chung J, Florentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 358: 70.
36. Calvo V, Crews CM, Vik TA, Bierer BE. Interleukin-2 stimula tion of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci USA 1992; 89: 7571.
37. Terada N, Franklin RA, Lucas JJ, Blenis J, Gelfand EW. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle, despite inactivation of p70 S6 kinase. J Biol Chem 1993; 268: 12062.
38. cdc2 kinase activation in T lymphocytes. J Biol Chem 1993; 268: 22737.
39. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gel fand EW. Rapamycin blocks cell cycle progression of activated T cell prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993; 154: 7.
40. Udhayakumar V, Brodeur PH, Rajagopalan MS, Zimmer S, Pol-lok K, Subbarao B. Isolation and immunological characterization of a group of new B lymphomas from CBA mice. Clin Immunol Immunopathol 1989; 51: 240.
41. Udhayakumar V, Muthukkumar S, Subbarao B. Cyclosporin A blocks surface IgM mediated growth inhibition in an immature B lymphoma, BKS-2. Eur J Immunol 1991; 21: 2605.
42. Muthukkumar S, Udhayakumar V, Bondada S. Elevation of cytosolic calcium is sufficient to induce growth inhibition in a B cell lymphoma. Eur J Immunol 1993; 23: 2419.
43. + lineage of B lymphocyte differentiation. J Immunol 1984; 133: 744.
44. Pillemer E, Whitlock C, Weissman IL. Transformation-associ ated proteins in murine B cell lymphomas that are distinct from Abelson virus gene products. Proc Natl Acad Sci USA 1984; 81: 4434.
45. Leptin M. Monoclonal antibodies for murine IgM. II. Activation of B cells by monoclonal antibodies specific for the four constant domains of IgM. Eur J Immunol 1985; 15: 131.
46. Udhayakumar V, Kumar L, Subbarao B. The influence of avidity on signaling murine B lymphocytes with monoclonal anti-IgM antibodies. Effects on B cell proliferation versus growth inhibition (tolerance) of an immature B cell lymphoma. J Immunol 1991; 146: 4120.
47. Strauss WM. Current protocols in molecular biology. New York: Greene Publishing Associates and Wiley-Interscience, 1987: 2. 2. 1.
48. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH. The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
49. Nossal GJV. Cellular mechanisms of immunological tolerance. Annu Rev Immunol 1983; 1: 33.
50. Banerjee P, Ahmed MF, Grove JR, Kozlosky C, Price DJ, Avruch J. Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase. Proc Natl Acad Sci USA 1990; 87: 8550.
51. 6k is associated with phosphorylation of four clustered sites displaying Ser/Thr-Pro motifs. Proc Natl Acad Sci USA 1992; 89: 7282.
52. 8βk function essential for G1 progression. Nature 1993; 363: 170.
53. Bβk activation mediated by phosphatidylionositol-3-OH kinase. Nature 1994; 370: 71.
54. Nurse P, Bissett Y. Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast. Nature 1981; 292: 558.
55. Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, Griffin JD. Cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science 1990; 250: 805.
56. cdc2 phosphorylation and histone HI kinase activity is associated with Gl/S phase growth arrest. Mol Cell Biol 1991; 11: 1185.
57. Draetta G. Cell cycle control in eukaryotes: molecular mecha nisms of cdc-2 activation. Trends Biol Sci 1990; 15: 378.
58. McDonnel TJ, Deane N, Platt FM, et al. bcl2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79.
59. Vaux DL, Cory S, Adams JM. bcl2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440.
60. Cuende E, Ales-Martinez JE, Ding L, Gonzalez-Garcia M, Mar-tinez-AC, Nunez G. Programmed cell death by bcl2 dependent and independent mechanisms in B lymphoma cells. EMBO J 1993; 12: 1555.